SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alivus Life Sciences - Quaterly Results

01 Aug 2025 Evaluate
The quarter ended June 2025 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 6018.46 millions.The Company has registered profit of Rs. 1215.35  millions for the quarter ended June 2025, a growth of 9.02%  over Rs. 1114.83 millions millions achieved in the corresponding quarter of last year.Operating profit for the quarter ended June 2025 rose to 1812.96 millions as compared to 1649.78 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 6018.46 5886.16 2.25 6018.46 5886.16 2.25 23868.84 22832.14 4.54
Other Income 89.85 54.93 63.57 89.85 54.93 63.57 345.70 120.42 187.08
PBIDT 1812.96 1649.78 9.89 1812.96 1649.78 9.89 7171.54 6862.88 4.50
Interest 12.51 3.53 254.39 12.51 3.53 254.39 24.14 15.46 56.14
PBDT 1800.45 1646.25 9.37 1800.45 1646.25 9.37 7147.40 6847.42 4.38
Depreciation 170.64 143.87 18.61 170.64 143.87 18.61 606.09 534.52 13.39
PBT 1629.81 1502.38 8.48 1629.81 1502.38 8.48 6541.31 6312.90 3.62
TAX 414.46 387.55 6.94 414.46 387.55 6.94 1685.04 1604.02 5.05
Deferred Tax 25.10 12.38 102.75 25.10 12.38 102.75 60.64 81.88 -25.94
PAT 1215.35 1114.83 9.02 1215.35 1114.83 9.02 4856.27 4708.88 3.13
Equity 245.26 245.05 0.09 245.26 245.05 0.09 245.07 245.05 0.01
PBIDTM(%) 30.12 28.03 7.48 30.12 28.03 7.48 30.05 30.06 -0.04

Alivus Life Sciences Share Price

1046.50 3.30 (0.32%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×